Dilon Technologies' Slant15(TM) and LEHR Collimators Enhance Imaging Capabilities

Wednesday, February 4, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

NEWPORT NEWS, Va., Feb. 3 Dilon Technologies, Inc., aleader in molecular breast imaging, today announced the release of two newcollimators: the Slant15 Collimator for breast imaging and the Low EnergyHigh-Resolution (LEHR) Collimator. Both collimators are attachment options forthe Dilon 6800 Gamma Camera that help to optimize imaging for the respectiveapplications.

The Slant15 Collimator is a 15-degree slant parallel-hole collimator thatminimizes the dead space along the edge of the detector, allowing bettervisualization of the chest wall in breast imaging. Uses include: breastimaging; sentinel node imaging; thyroid imaging; and parathyroid imaging.

LEHR collimator is a high-resolution collimator for general nuclearmedicine applications. Uses include thyroid imaging, parathyroid imaging,sentinel node imaging, spot bone imaging, gall bladder ejection, and pediatricimaging studies.

"With the release of these new collimators, we are expanding breastimaging and general nuclear applications for the Dilon 6800 Gamma," said BobMoussa, President and CEO of Dilon Technologies. "This is another step inproviding a broader service offering to clinicians."

About Dilon Technologies

Dilon Technologies, Inc. is bringing innovative new medical imagingproducts to market. Dilon's cornerstone product, the Dilon 6800, is ahigh-resolution, small field-of-view gamma camera, optimized to perform BSGI,a molecular breast imaging procedure which images the metabolic activity ofbreast lesions through radiotracer uptake. Many leading medical centers aroundthe country are now offering BSGI to their patients, including: CornellUniversity Medical Center, New York; George Washington University MedicalCenter, Washington, D.C.; and The Rose, Houston.

For more information on Dilon Technologies please visithttp://www.dilon.com.

SOURCE Dilon Technologies, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store